A Behavioral Modification Strategy for Newly Diagnosed OAB
Urology
Curriculum:
Case Clinic: Taking a More Aggressive Approach for Treatment of Persistent OAB Symptoms
Case Clinic: Taking a More Aggressive Approach for Treatment of Persistent OAB Symptoms
Credits:
0.5 ANCC Contact Hours 0.5 AMA PRA Category 1 Credit(s) ™ 0.5 CPD
0.5 ANCC Contact Hours 0.5 AMA PRA Category 1 Credit(s) ™ 0.5 CPD
Launch Date:
May 31, 2017
May 31, 2017
Expiration Date:
The accreditation for this activity has expired.
The accreditation for this activity has expired.
Primary Audience:
Urologists, urogynecologists, obstetrician-gynecologists (ob-gyns), primary care physicians, physician assistants, nurses
Relevant Terms:
Genitourinary medicine, Obstetrics, general practice, internal medicine
Kyu-Sung Lee, MD, PhD
Kyu-Sung Lee, MD, PhD
Professor, Department of Urology
General Director, Biomedical Engineering Research Center
Samsung Medical Center
Sungkyunkwan University School of Medicine
Seoul, South Korea
Bio
Dr. Kyu-Sung Lee is Executive Vice President at Samsung BioLogics Co., Ltd. Dr. Lee was previously employed as a Principal by Bristol-Myers Squibb Co., a Principal by Merck & Co., Inc., a Principal by Amoco Bioproducts, and Biochemical Engineer by Miller Brewing Co.
| 1. | Evaluate overactive bladder (OAB), particularly in the presence of comorbidities, considering the impact on quality of life | 2. | Inform patients about current and emerging therapeutic options and strategies for managing OAB, focusing on the patient's needs and assessing efficacy, tolerability, and optimal adherence |
| 3. | Engage in more effective provider-patient dialogues to identify the patient's needs and improve outcomes for OAB | 4. | Provide proper counseling and support to patients with OAB to increase their motivation for treatment-plan adherence and to improve patient quality of life |
| 1. | Evaluate overactive bladder (OAB), particularly in the presence of comorbidities, considering the impact on quality of life |
| 2. | Inform patients about current and emerging therapeutic options and strategies for managing OAB, focusing on the patient's needs and assessing efficacy, tolerability, and optimal adherence |
| 3. | Engage in more effective provider-patient dialogues to identify the patient's needs and improve outcomes for OAB |
| 4. | Provide proper counseling and support to patients with OAB to increase their motivation for treatment-plan adherence and to improve patient quality of life |
Program Description
The American Urological Association and the European Association of Urology recommend a number of non-invasive, pharmacologic, and surgical options that can help reduce the symptoms of OAB, including lifestyle and behavioral changes as first-line therapy in OAB. There is clear support for the effectiveness of bladder training (incremental voiding schedules done with distraction and self-assertions) and behavioral training (pelvic floor muscle training with urge suppression techniques) to reduce the symptoms of OAB. Typical mean improvements range from a 50% to 80% reduction in the frequency of incontinence. Voiding frequency can also be reduced in men and women. This case report covers a breadth of recommended behavior techniques that can be effective in a patient with modest new-onset OAB.
The American Urological Association and the European Association of Urology recommend a number of non-invasive, pharmacologic, and surgical options that can help reduce the symptoms of OAB, including lifestyle and behavioral changes as first-line therapy in OAB. There is clear support for the effectiveness of bladder training (incremental voiding schedules done with distraction and self-assertions) and behavioral training (pelvic floor muscle training with urge suppression techniques) to reduce the symptoms of OAB. Typical mean improvements range from a 50% to 80% reduction in the frequency of incontinence. Voiding frequency can also be reduced in men and women. This case report covers a breadth of recommended behavior techniques that can be effective in a patient with modest new-onset OAB.
Provided by Global Education Group in Collaboration With Haymarket Medical Education.
Supported by an educational grant from Astellas.
Faculty Information
Kyu-Sung Lee, M.D., PhD.
Professor, Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine
General Director
Biomedical Engineering Research Center
Samsung Medical Center
KOREA
Faculty Disclosures
Kyu-Sung Lee, M.D., PhD., is a consultant for Astellas Asia-Pacific and recieves Grant/Reserch support.
Publishing Staff Disclosures
Susan Basilico, Angie Ladas and Nick Zittell have nothing to disclose
Accreditation Statement(s)
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Astellas or Global Education Group. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. If you have any questions relating to the accreditation of this activity, please contact Global at 303-395-1782 or inquire@globaleducationgroup.com
Method of Participation Instructions
To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate.
Kyu-Sung Lee, M.D., PhD.
Professor, Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine
General Director
Biomedical Engineering Research Center
Samsung Medical Center
KOREA
Faculty Disclosures
Kyu-Sung Lee, M.D., PhD., is a consultant for Astellas Asia-Pacific and recieves Grant/Reserch support.
Publishing Staff Disclosures
Susan Basilico, Angie Ladas and Nick Zittell have nothing to disclose
Accreditation Statement(s)
Physician Credit: Global Education Group is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Nursing Credit: Global Education Group is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
Credit Designation Statement(s)
Nursing Credit: Global Education Group is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
Credit Designation Statement(s)
Physician Credit Designation: Global Education Group designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Credit Designation: This educational activity for 0.50 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Astellas or Global Education Group. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. If you have any questions relating to the accreditation of this activity, please contact Global at 303-395-1782 or inquire@globaleducationgroup.com
Method of Participation Instructions
To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate.
Privacy Policy
http://www.mycme.com/privacypolicy/
| Supported Browsers: Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above Google Chrome 28.0+ for Windows, Mac OS, or Linux Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux Safari 6.0+ for Mac OSX 10.7 and above | Supported Phones & Tablets: Android 4.0.3 and above iPhone/iPad with iOS 6.1 or above. |
© 2007-2025 HealthCourse, Inc. All rights reserved.
